Bladder Cancer

Defining Factors Associated with High-quality Surgery Following Radical Cystectomy: Analysis of the British Association of Urological Surgeons Cystectomy Audit

Wei Shen Tan a, b, *, Jeffrey J. Leow d, e, Maya Marchese f, Ashwin Sridhar a, c, Giles Hellawell g, Matthew Mossanen h, Jeremy Y.C. Teoh i, Sarah Fowler j, Alexandra J. Colquhoun k, Jo Cresswell l, James W.F. Catto m, Quoc-Dien Trinh h, j, John D. Kelly a, c, 1 on behalf of the BAUS Section of Oncology

a Division of Surgery & Interventional Science, University College London, London, UK; b Department of Urology, Royal Free London NHS Foundation Trust, London, UK; c Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK; d Department of Urology, Tan Tock Seng Hospital, Singapore; e Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; f Center for Surgery and Public Health, Division of Urological Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; g Department of Urology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK; h Lank Center for Genitourinary Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA, USA; i The S H Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong; j British Association of Urological Surgeons, London, UK; k Department of Urology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; l Department of Urology, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK; m Academic Urology Unit, University of Sheffield, Sheffield, UK

Article info

Article history:
Accepted August 24, 2021

Associate Editor:
Guillaume Ploussard

Keywords:
British Association of Urological Surgeons audit
Bladder cancer
Centralisation
Quality surgery
Radical cystectomy
Outcomes

Abstract

**Background:** Radical cystectomy (RC) is associated with high morbidity.

**Objective:** To evaluate healthcare and surgical factors associated with high-quality RC surgery.

**Design, setting, and participants:** Patients within the prospective British Association of Urological Surgeons (BAUS) registry between 2014 and 2017 were included in this study.

**Outcome measurements and statistical analysis:** High-quality surgery was defined using pathological (absence of positive surgical margins and a minimum of a level I lymph node dissection template with a minimum yield of ten or more lymph nodes), recovery (length of stay \( \leq 10 \) d), and technical (intraoperative blood loss <500 ml for open and <300 ml for minimally invasive RC) variables. A multilevel hierarchical mixed-effect logistic regression model was utilised to determine the factors associated with the receipt of high-quality surgery and index admission mortality.

**Results and limitations:** A total of 4654 patients with a median age of 70.0 yr underwent RC by 152 surgeons at 78 UK hospitals. The median surgeon and

---

1 Joint senior author.

* Corresponding author. Division of Surgery & Interventional Science, University College London, 3rd floor Charles Bell House, 43-45 Foley Street, London W1W 7TS, UK.

E-mail address: wei.tan@ucl.ac.uk (W.S. Tan).
hospital operating volumes were 23.0 and 47.0 cases, respectively. A total of
914 patients (19.6%) received high-quality surgery. The minimum annual surgeon
volume and hospital volume of ≥20 RCs/surgeon/yr and ≥68 RCs/hospital/yr,
respectively, were the thresholds determined to achieve better rates of high-quality
RC. The mixed-effect logistic regression model found that recent surgery (odds ratio
[OR]: 1.22, 95% confidence interval [CI]: 1.11–1.34, p < 0.001), laparoscopic/robotic
RC (OR: 1.85, 95% CI: 1.45–2.37, p < 0.001), and higher annual surgeon operating
volume (23.1–33.0 cases [OR: 1.54, 95% CI: 1.16–2.05, p = 0.003]; ≥33.1 cases [OR:
1.64, 95% CI: 1.18–2.29, p = 0.003]) were independently associated with high-quality
surgery. High-quality surgery was an independent predictor of lower index admiss-
im mortality (OR: 0.38, 95% CI: 0.16–0.87, p = 0.021).

Conclusions: We report that annual surgeon operating volume and use of mini-
mally invasive RC were predictors of high-quality surgery. Patients receiving high-
quality surgery were independently associated with lower index admission mor-
tality. Our results support the role of centralisation of complex oncology and
implementation of a quality assurance programme to improve the delivery of care.

Patient summary: In this registry study of patients treated with surgical excision of
the urinary bladder for bladder cancer, we report that patients treated by a surgeon
with a higher annual operative volume and a minimally invasive approach were
associated with the receipt of high-quality surgery. Patients treated with high-
quality surgery were more likely to be discharged alive following surgery.

© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association
of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Radical cystectomy (RC) with lymph node dissection (LND) is the recommended
treatment for muscle-invasive bladder cancer (MIBC) and selected high-risk non–muscle-invasive
bladder cancer [1,2]. RC can be a technically challenging procedure, often performed in patients with pre-existing
comorbidities [3] with a competing risk of mortality [4]. Complications and morbidity after RC are common
[5], and a variety of factors influence postoperative oncological and nononcological outcomes [6,7].

Efforts to improve outcomes from RC through standardised care pathways have been included in various guide-
lines [8,9] and have led to the centralisation of complex pelvic cancer services in the UK [10–12]. Despite these
approaches, outcomes following RC vary widely [11,13], reflecting differences in practice, case volume/outcome
relationships, and adherence to guidelines. Nevertheless, variation of care following RC despite centralisation of care
remains, suggesting that a magnitude of factors, other than the volume-outcome relationship, influence perioperative
outcomes.

Defining high-quality surgery is a subject of debate, but there are several uniform consensuses that we have
identified in our recent collaborative review [14]. While cancer stage and positive lymph node status influence
cancer survival rates, surgical technique to minimise positive surgical margin (PSM) status and adequate LND
remains crucial [15]. Hence, the absence of a pathological
PSM [14,16] and a template LND [14,17] with a minimum
LND count is paramount [15]. A surrogate for surgical
technique would be surgical blood loss [18] and hospital
length of stay (LOS) [19], which would be impacted by
perioperative complications [20]. LOS was used as a
surrogate of enhanced recovery pathways and clinically
meaningful complications, and can be used as a surrogate
measure of recovery [21–24].

In 2013, the British Association of Urological Surgeons
(BAUS) mandated that all RCs performed in the UK should
be recorded prospectively in a registry. We utilised this
database to interrogate factors associated with our pre-
defined high-quality surgery indicators.

2. Patients and methods

2.1. Patient selection

Patients included in this analysis were nonmetastatic bladder cancer
patients who underwent RC between January 2014 and December
2017 across the UK and entered into the BAUS registry. Data were
prospectively self-submitted by individual surgeons (or their hospital
delegates). Surgeons were provided two opportunities to check/validate
the data recorded to ensure accuracy. Cases within the registry represent
approximately >80% of all RC surgeries performed in the UK according to
NHS data [25].

2.2. Variables of interest

The following patient-specific variables were extracted: patient age at
diagnosis (continuous), gender (male and female), Charlson Comorbidity
Index (CCI; 0, 1, 2, and ≥3), anaerobic threshold (AT) based on
cardiopulmonary exercise tolerance testing (<11 and ≥11), body mass
index (BMI) by quartiles (<24.7, 24.8–27.4, 27.5–30.5, and ≥30.6),
preoperative anaemia (yes or no), preoperative chemotherapy use (yes or no), preoperative radiotherapy use (yes or no), hospital LOS, and year of surgery (2014, 2015, 2016, and 2017).

The surgical-related factors extracted included the following: urinary diversion type (ileal conduit, continent diversion, and other), surgical approach (open and minimally invasive [robotic/laparoscopic]), operating surgeon volume by quartiles (<14, 14.1–23.0, 23.1–33.0, and ≥33.1), hospital case volume by quartiles (<29.0, 29.1–47.0, 47.1–63.0, and ≥63.1), estimated blood loss (<299, 300–499, 500–999, and >1000 ml), requirement for blood transfusion (yes or no), and number of pack red blood cells transfused (1–2 and ≥3 units). Cancer-specific variables extracted included the following: cancer grade (G1/2 and G3), clinical cancer stage (<T1, T1, and T3/4), clinical nodal stage (N1+ and N0), and PSM status (yes or no), and adequate LND (yes or no).

Patients with missing data for the following variables were excluded from analysis: LND template, lymph node yield count, PSM status, hospital LOS, surgical technique, blood loss, and inpatient mortality (Fig. 1).

2.3. High-quality surgery

High-quality surgery was defined as surgery in patients who had (1) a negative surgical margin, (2) adequate LND, (3) hospital LOS ≤ 10 d, and (4) minimal intraoperative estimated blood loss [15,26]. PSM was defined as any soft tissue or carcinoma in situ (CIS) at surgical margin. Adequate LND was defined as a minimum of level I LND with a lymph node yield of ten or more nodes. Minimal blood loss was defined as <500 ml blood loss for open RC cases and <300 ml for minimally invasive RC cases.

The variables that we identified to determine high-quality surgery were defined based on well-validated variables of good outcomes following surgery. PSM has been shown to be independently associated with cancer-specific survival following RC [14,16]. We defined the removal of a minimum of ten or more lymph nodes at RC as a benchmark, as it has been shown to be a predictor of a superior oncological outcome [15]. This is in combination with a minimum of a level I LND as an extended LND is not superior to a limited LND [14,17]. A hospital LOS threshold of ≤10 d was used, as it represents the median LOS of the cohort. Intraoperative blood loss is often a surrogate for high-quality surgery and may be associated with increased mortality in noncardiac surgery [18]. The threshold of ≤300 ml was suggested in the Pasadena Consensus to define experienced robot-assisted RC (RARC) surgeons [18,27]. RARC has been shown to be associated with lower blood loss than open RC; hence, we accounted for this using different thresholds when defining quality surgery [28].

2.4. Statistical analysis

Categorical variables were reported using descriptive statistics, frequency, and proportions. Continuous variables were reported using median and interquartile range (IQR). To determine bivariate differences between patient groups, χ² and Wilcoxon tests were used for categorical and continuous variables, respectively. Annual hospital volume and surgeon volume were categorised to deciles, and minimally required annual surgical volume to achieve higher high-quality surgery was determined using the minimum p-value approach [29]. To adjust for clustering within treating hospitals, we utilised a random-effect model to account for individual treating hospitals [30,31]. Subsequently, a mixed-effect logistic regression model was utilised to predict the odds of a patient receiving high-quality surgery and index admission mortality following adjustment for patient-, cancer-, and hospital-related factors. Sensitivity analysis was performed to determine the association between hospital LOS and index admission mortality to ensure shorter hospital LOS, which was a quality matrix and was not attributed to early postoperative mortality. Hospitals were then ranked from least likely to most likely achieving high-quality surgery following RC and plotted against the probability of high-quality surgery to obtain a caterpillar graph.

Data analysis was performed using Stata 15 (StataCorp, College Station, TX, USA). A two-sided p value of <0.05 was considered statistically significant. This project was approved by the BAUS Oncology Council. In accordance with the UK National Research Ethics Service guidelines, ethical approval was not required.

3. Results

3.1. Cohort

A total of 4654 patients with a median age of 70.0 (IQR: 63.0–75.0) yr underwent RC at 78 institutions by 152 surgeons. The median annual RC caseload was 23.0 (IQR: 14.0–33.0) cases per surgeon and 47.0 (IQR: 29.0–63.0) cases per hospital. A total of 1731 patients (37.2%) at 42 hospitals received minimally invasive RC. Of the 2775 MIBC patients, a total of 667 (24.0%) received neoadjuvant chemotherapy (NAC), while 268 (5.8%) had a salvage RC after radiotherapy. Continent diversion was constructed for 293 patients (6.3%).

3.2. Outcomes in quality metrics

A total of 455 patients (12.2%) had a PSM, including 222 patients (5.9%) with soft tissue/circumferential involvement and 119 (3.2%), 83 (2.2%), and 31 (0.8%) patients with ureteric, urethral, and unknown margins, respectively (Table 1). The soft tissue PSM rate for pT2 patients was 0.5%. The median lymph node yield was 13.0 (IQR: 8.0–19.0), and 3214 patients (69.1%) had a lymph node yield of ten or more nodes. A total of 3142 patients (67.5%) met our “adequate LND” definition. Mortality following admission for RC was observed in 1.8%, and the median hospital LOS was 10.0
| Table 1 – Baseline patient, hospital, and cancer-specific variables stratified by high-quality surgery status |
|---------------------------------------------------------------|----------------------------------|------------------------|------------------------|------------------------|
| All patients (n = 4654)                                      | High-quality surgery (n = 914)   | Not high-quality surgery (n = 3740) | p value                      |
| Age at diagnosis (yr), mean ± standard error mean           | 69.7 ± 0.3                      | 68.1 ± 0.6              | 70.1 ± 0.3              | 0.002                  |
| Gender, n (%)                                                |                                 |                        |                        | 0.195                  |
| Male                                                         | 3495 (75.1)                     | 702 (76.8)             | 2793 (74.7)             |                        |
| Female                                                       | 1152 (24.8)                     | 212 (23.2)             | 940 (25.1)              |                        |
| Unknown                                                      | 7 (0.1)                         | 0 (0)                  | 7 (0.2)                 |                        |
| Charlson Comorbidity Index, n (%)                           | 1924 (41.4)                     | 417 (45.6)             | 1507 (40.3)             | <0.001                 |
| 0                                                            | 687 (14.8)                      | 134 (14.7)             | 553 (14.8)              |                        |
| 1                                                            | 756 (16.2)                      | 135 (14.8)             | 621 (16.6)              |                        |
| ≥3                                                           | 620 (13.3)                      | 85 (9.3)               | 535 (14.3)              |                        |
| Unknown                                                      | 667 (14.3)                      | 143 (15.6)             | 524 (14.0)              |                        |
| Anaerobic threshold, n (%)                                   | 380 (8.2)                       | 73 (8.0)               | 307 (8.2)               | 0.006                  |
| <11                                                          | 628 (13.5)                      | 153 (16.7)             | 475 (12.7)              |                        |
| ≥11                                                          | 3646 (78.3)                     | 688 (75.3)             | 2958 (79.1)             |                        |
| BMI, n (%)                                                   | 848 (18.2)                      | 187 (20.5)             | 661 (17.7)              | <0.001                 |
| <24.7                                                        | 879 (18.9)                      | 187 (20.5)             | 692 (18.5)              |                        |
| 24.8–27.4                                                    | 861 (18.5)                      | 174 (19.0)             | 687 (18.4)              |                        |
| ≥30.6                                                        | 851 (18.3)                      | 121 (13.2)             | 730 (19.5)              |                        |
| Unknown                                                      | 1215 (26.1)                     | 245 (26.8)             | 970 (25.9)              |                        |
| Nonsurgical chemotherapy use, n (%)                         | 1100 (23.6)                     | 261 (28.5)             | 839 (22.4)              | <0.001                 |
| No                                                           | 667 (14.4)                      | 155 (17.0)             | 512 (13.7)              |                        |
| Yes                                                          | 2887 (62.0)                     | 498 (54.5)             | 2389 (63.9)             |                        |
| Preoperative radiotherapy, n (%)                             | 3672 (78.9)                     | 794 (86.9)             | 2878 (76.9)             | <0.001                 |
| No                                                           | 268 (5.8)                       | 18 (2.0)               | 250 (6.7)               |                        |
| Yes                                                          | 714 (15.3)                      | 102 (11.1)             | 612 (16.4)              |                        |
| Year of surgery, n (%)                                       | 1037 (22.3)                     | 136 (14.9)             | 901 (24.1)              | <0.001                 |
| 2014                                                         | 1216 (26.1)                     | 260 (28.4)             | 956 (25.5)              |                        |
| 2015                                                         | 1247 (26.8)                     | 246 (26.9)             | 1001 (26.8)             |                        |
| 2016                                                         | 1154 (24.8)                     | 272 (29.8)             | 882 (23.6)              |                        |
| Urinary diversion type, n (%)                                | 4217 (90.6)                     | 867 (94.9)             | 3350 (89.6)             | <0.001                 |
| Ileal conduit                                                | 293 (6.3)                       | 32 (3.5)               | 261 (7.0)               |                        |
| Continent                                                    | 89 (1.9)                        | 5 (0.5)                | 84 (2.2)                |                        |
| Other                                                        | 55 (1.2)                        | 10 (1.1)               | 45 (1.2)                |                        |
| Surgical approach, n (%)                                     | 2923 (62.8)                     | 413 (45.2)             | 2510 (67.1)             | <0.001                 |
| Open                                                         | 1731 (37.2)                     | 501 (54.8)             | 1230 (32.9)             |                        |
| Laparoscopic/robotic                                         | 1196 (25.7)                     | 167 (18.3)             | 1029 (27.5)             | <0.001                 |
| Annual surgeon operating volume, n (%)                      | 1275 (27.4)                     | 233 (25.5)             | 1042 (27.8)             |                        |
| ≤14.0                                                        | 1036 (22.3)                     | 248 (27.1)             | 788 (21.1)              |                        |
| 14.1–23.0                                                    | 1147 (24.6)                     | 266 (29.1)             | 881 (23.6)              |                        |
| Annual hospital operating volume, n (%)                     | 1268 (27.3)                     | 202 (22.1)             | 1006 (28.5)             | 0.001                  |
| ≤29.0                                                        | 1132 (24.3)                     | 241 (26.4)             | 891 (23.8)              |                        |
| 29.1–47.0                                                    | 1201 (25.8)                     | 241 (26.4)             | 960 (25.7)              |                        |
| ≥47.1–63.0                                                   | 1053 (22.6)                     | 230 (25.1)             | 823 (22.0)              |                        |
| Blood loss (ml), n (%)                                       | 1444 (31.0)                     | 646 (70.7)             | 798 (21.3)              | <0.001                 |
| ≤299                                                         | 1361 (29.2)                     | 268 (29.3)             | 1093 (29.2)             |                        |
| 300–499                                                      | 1222 (26.3)                     | 0 (0)                  | 1222 (32.7)             |                        |
| 500–999                                                      | 627 (13.5)                      | 0 (0)                  | 627 (16.8)              |                        |
| ≥1000                                                        | 74 (1.6)                        | 9 (1.0)                | 65 (1.7)                |                        |
| Red blood cell transfusion, n (%)                            | 3838 (82.5)                     | 875 (95.7)             | 2963 (79.2)             | <0.001                 |
| No                                                           | 742 (15.9)                      | 30 (3.3)               | 712 (19.1)              |                        |
| Yes                                                          | 74 (1.6)                        | 9 (1.0)                | 65 (1.7)                |                        |
| Red blood cell transfusion, n (%)                            | 3838 (82.5)                     | 875 (95.7)             | 2963 (79.2)             | <0.001                 |
| No                                                           | 525 (11.3)                      | 29 (3.2)               | 496 (13.3)              |                        |
| 1–2 units                                                    | 247 (4.6)                       | 1 (0.1)                | 216 (5.8)               |                        |
| ≥3 units                                                     | 74 (1.6)                        | 9 (1.0)                | 65 (1.7)                |                        |
| Tumour grade, n (%)                                          | 306 (6.6)                       | 55 (6.0)               | 251 (6.7)               | 0.733                  |
| Low                                                          | 3578 (76.9)                     | 709 (77.6)             | 2869 (76.7)             |                        |
| High                                                         | 1230 (26.9)                     | 266 (29.1)             | 881 (23.6)              |                        |
(IQR: 7.0–14) d. A total of 914 patients (19.6%) who were operated by 109 surgeons (71.7%) at 65 hospitals (83.3%) fulfilled all four high-quality surgery metrics.

### 3.3. Factors associated with high-quality surgery

Table 1 reports baseline patient, hospital, and cancer-specific variables stratified by high-quality surgery status. Patients who were younger (p = 0.035); had a lower CCI (< 0.001), higher AT (p = 0.006), and lower BMI (p < 0.001); did not receive NAC (p < 0.001); did not receive radiotherapy (p < 0.001); had more recent surgery (p < 0.001); received ileal conduit (p < 0.001); were operated by a minimally invasive approach (p < 0.001); had higher annual surgeon (p < 0.001) and hospital (p = 0.001) operating volume; had minimal blood loss (p < 0.001); did not require red blood cell transfusion (p < 0.001); had a lower number of transfused blood units (p < 0.001); and were with absence of lymph node disease (p = 0.025) were significantly associated with the attainment of high-quality surgery. Minimum annual surgeon and hospital volumes of ≥20 cystectomies/surgeon/yr and ≥68 cystectomies/hospital/yr were, respectively, the thresholds determined to achieve better rates of high-quality RC (Supplementary Table 1).

Multilevel hierarchical mixed-effect logistic regression was utilised to determine variables independently associated with high-quality surgery (Table 2). Older patients (odds ratio [OR]: 0.99, 95% confidence interval [CI]: 0.99–1.00, p = 0.010), higher CCI (≥3 [OR: 0.64, 95% CI: 0.47–0.85, p = 0.005]), higher BMI (≥30.6 [OR: 0.50, 95% CI: 0.38–0.67]), pN+ (OR: 0.77, 95% CI: 0.62–0.97, p = 0.023), preoperative radiotherapy (OR: 0.35, 95% CI: 0.21–0.58, p < 0.001), and continent diversion (OR: 0.38, 95% CI: 0.25–0.57, p < 0.001) were independently associated with a lower likelihood of high-quality surgery. Minimally invasive (laparoscopic/robotic) RC (OR: 1.85, 95% CI: 1.45–2.37, p < 0.001), higher annual surgeon operating volume (23.1–33.0 [OR: 1.54, 95% CI: 1.16–2.05, p = 0.003]; ≥33.1 [OR: 1.64, 95% CI: 1.18–2.29, p = 0.003]), and more recent surgery year (OR: 1.22, 95% CI: 1.11–1.34, p < 0.001) were independently associated with receiving high-quality surgery. The sensitivity analysis performed following the exclusion of AT, BMI, and NAC from the multilevel hierarchical mixed-effect logistic regression model due to >20% missing values reaffirms our findings. Figure 2 shows a caterpillar plot depicting the individual surgeon-adjusted risk of high-quality surgery following adjustment for other factors.

We subsequently confirmed, using multilevel hierarchical mixed-effect logistic regression, that patients who achieved high-quality surgery were significantly less likely to have index admission mortality (OR: 0.38, 95% CI: 0.16–0.87, p = 0.021; Table 3). This finding was consistent even after the exclusion of AT, BMI, and NAC from the multilevel hierarchical mixed-effect logistic regression model (OR: 0.37, 95% CI: 0.16–0.85, p = 0.019). A sensitivity analysis suggests that the mean hospital LOS was significantly shorter in patients discharged alive than in patients who had an inpatient death (12.9 vs 28.2 d, p < 0.001). Other factors associated with an increased risk of index admission death include pT3–4 (OR: 2.17, 95% CI: 1.20–3.94, p = 0.011) and ≥3 units of blood transfused (OR: 3.5, 95% CI: 1.54–8.17, p = 0.003).

### 4. Discussion

We report that one in five patients who underwent RC between 2014 and 2017 achieved our definition of high-quality surgery. Annual surgeon operating volume (but not annual hospital operating volume) was a predictor of the attainment of high-quality surgery. Minimally invasive RC and more recent year of surgery were other factors that predicted achievement of high-quality surgery. Patients who received high-quality surgery were more likely to be discharged alive following RC. Significant variability exists at an individual surgeon level in the attainment of high-quality surgery.

Defining high-quality surgery is essential to prove good-quality care. Particularly in the case for RC, a complex procedure with high morbidity and mortality, identification of providers of high-quality surgery care would allow clinicians and administrators to audit and improve

---

### Table 1 (Continued)

|                          | All patients (n = 4654) | High-quality surgery (n = 914) | Not high-quality surgery (n = 3740) | p value |
|--------------------------|-------------------------|-------------------------------|------------------------------------|---------|
| Unknown                  |                         |                               |                                    |         |
| Pathological T stage, n (%) |                        |                               |                                    |         |
| ≤pT1                     | 1889 (40.6)             | 390 (42.7)                    | 1499 (40.0)                        |         |
| pT2                      | 786 (16.9)              | 169 (18.5)                    | 617 (16.5)                         |         |
| pT3–4                    | 1833 (39.4)             | 323 (35.3)                    | 1510 (40.4)                        |         |
| Unknown                  | 146 (3.1)               | 32 (3.5)                      | 114 (3.0)                         |         |
| Pathological N stage, n (%) |                        |                               |                                    |         |
| pNO                      | 3411 (73.3)             | 729 (79.7)                    | 2682 (71.7)                        | <0.001  |
| pN+                      | 916 (19.7)              | 166 (18.2)                    | 750 (20.1)                         |         |
| Unknown                  | 327 (7.0)               | 19 (2.1)                      | 308 (8.2)                         |         |
| Type of positive surgical margin, n (%) |         |                               |                                    |         |
| Vesical                   | 222 (5.9)               | 222 (5.9)                     |                                    |         |
| Ureteric                 | 119 (3.2)               | 119 (3.2)                     |                                    |         |
| Urethral                 | 83 (2.2)                | 83 (2.2)                      |                                    |         |
| Unknown                  | 31 (0.8)                | 31 (0.8)                      |                                    |         |

BMI = body mass index.
Table 2 – Multilevel hierarchical mixed-effect logistic regression model to determine variables independently associated with high-quality surgery in bladder cancer patients treated with radical cystectomy

| Variables                                         | Odds ratio | 95% CI | p value |
|---------------------------------------------------|------------|--------|---------|
| **Patient-specific variables**                    |            |        |         |
| Age (continuous)                                   | 0.91       | 0.012  | 0.84–0.98 |
| Charlson Comorbidity Index                        | Reference  | Reference |      |
| 0                                                 | Reference  | Reference |      |
| 1                                                 | 0.85       | 0.67–1.08 | 0.190 |
| 2                                                 | 0.80       | 0.62–1.03 | 0.083 |
| ≥3                                                | 0.65       | 0.48–0.88 | 0.005 |
| Unknown                                           | 0.81       | 0.58–1.13 | 0.219 |
| Anaerobic threshold                               |            |        |         |
| <11                                               | Reference  | Reference |      |
| ≥11                                               | 1.36       | 0.95–1.95 | 0.090 |
| Unknown                                           | 1.43       | 0.53–1.17 | 0.042 |
| BMI                                               |            |        |         |
| <24.7                                             | Reference  | Reference |      |
| 24.8–27.4                                         | 0.81       | 0.63–1.05 | 0.111 |
| 27.5–30.5                                         | 0.78       | 0.60–1.01 | 0.057 |
| ≥30.6                                             | 0.50       | 0.38–0.67 | <0.001 |
| Unknown                                           | 0.89       | 0.67–1.17 | 0.408 |
| Neoadjuvant chemotherapy use                       |            |        |         |
| No                                                | Reference  | Reference |      |
| Yes                                               | 0.93       | 0.69–1.24 | 0.599 |
| Unknown                                           | 0.69       | 0.57–0.85 | <0.001 |
| Preoperative radiotherapy                         |            |        |         |
| No                                                | Reference  | Reference |      |
| Yes                                               | 0.35       | 0.21–0.59 | <0.001 |
| Unknown                                           | 0.88       | 0.65–1.20 | 0.416 |
| Urinary diversion type                            |            |        |         |
| Ileal conduit                                      | Reference  | Reference |      |
| Continent                                         | 0.37       | 0.25–0.57 | <0.001 |
| Other                                             | 0.35       | 0.14–0.92 | 0.033 |
| Unknown                                           | 0.89       | 0.41–1.90 | 0.756 |
| Year of surgery (continuous)                      | 1.22       | 1.11–1.34 | <0.001 |
| **Cancer-specific variables**                     |            |        |         |
| Tumour grade                                      |            |        |         |
| Low                                               | Reference  | Reference |      |
| High                                              | 0.97       | 0.69–1.36 | 0.843 |
| Unknown                                           | 0.79       | 0.53–1.17 | 0.234 |
| Pathological T stage                              |            |        |         |
| ≤pT1                                              | Reference  | Reference |      |
| pT2                                               | 1.01       | 0.80–1.27 | 0.945 |
| pT3–4                                            | 0.85       | 0.69–1.04 | 0.114 |
| Unknown                                           | 1.85       | 1.12–3.05 | 0.016 |
| Pathological N stage                              |            |        |         |
| ≤pN0                                              | Reference  | Reference |      |
| pN+                                               | 0.77       | 0.62–0.97 | 0.023 |
| Unknown                                           | 0.26       | 0.15–0.43 | <0.001 |
| **Hospital-level variables**                      |            |        |         |
| Surgical approach                                 |            |        |         |
| Open                                              | Reference  | Reference |      |
| Laparoscopic/robotic                              | 1.86       | 1.46–2.38 | <0.001 |
| **Annual surgeon operating volume**              |            |        |         |
| <14                                               | Reference  | Reference |      |
| 14.1–23.0                                         | 1.30       | 0.99–1.70 | 0.060 |
| 23.1–33.0                                         | 1.54       | 1.16–2.04 | 0.003 |
| ≥33.1                                             | 1.64       | 1.18–2.28 | 0.003 |
| **Annual hospital operating volume**             |            |        |         |
| <29.0                                             | Reference  | Reference |      |
| 29.1–47.0                                         | 0.94       | 0.68–1.29 | 0.685 |
| 47.1–63.0                                         | 0.80       | 0.55–1.16 | 0.238 |
| ≥63.1                                             | 0.75       | 0.43–1.28 | 0.290 |

BMI = body mass index; CI = confidence interval.

Performance. Acknowledging limitations of retrospective data, this study is important to promote organisation of complex cancer surgery and may be useful in the selection of centres of excellence, based on the hub-and-spoke model. In healthcare models that are based on fee for service models, such high-quality matrix may help inform patient's choice of hospital as well as guide insurance companies in deciding on preferred centres for referral.
Efforts to improve cancer outcomes have led to the centralisation of pelvic oncology services in the UK that commenced in 2002, where centres had to perform a minimum of 50 pelvic oncology cases per annum [32]. Between 2003 and 2013, the number of hospitals performing RC has decreased steadily with a corresponding increase in the number of cases performed per hospital, with >95% of cases being compliant with National Institute for Health and Care Excellence (NICE) recommendations [33]. The development of high-volume surgeons and hospitals has subsequently resulted in a reduction of 90-d mortality rates from 5.8% to 2.6% [33]. Indeed, our results suggest a strong correlation between annual surgeon operating volumes independent of confounding factors, although we did not observe this for annual hospital surgical volume. This suggests that intersurgeon variation whether in a form of operative technique or in terms of the postoperative convalescent period may be crucial. This highlights the importance of the implementation of a quality assurance programme to improve the collective outcome of patient case [34].

In a collaborative review that we recently published, we recommended that surgical quality indicators should include selection for continent diversion, receipt of NAC, adequacy of LND, blood loss, operative time, negative surgical margins, and standardised morbidity and mortality reporting [14]. Other groups have reported quality assessment tools to evaluate the performance of RC. Hussein et al [35] utilised variables including the use of NAC, operative time (<6.5 h) and blood loss (<500 ml), negative soft tissue surgical margins and lymph node yield (≥20), and freedom from high-grade complications, readmission, and noncancer 30-d mortality. Their quality cystectomy score was independently associated with cancer-specific, recurrence-free, and overall survival in robotic cystectomy patients [35]. Khanna et al [36] utilised the National Cancer Database to define a bladder cancer quality score (BCQS) utilising the following variables: PSM, LND, unplanned readmission rate ≤30 d from discharge, proportion of MIBC patients receiving NAC, proportion of patients receiving continent urinary diversion, postoperative LOS, and time of diagnosis from cystectomy. They reported that academic institutions were associated with a better BCQS, and this in turn was associated with lower 90-d disease-specific (HR: 0.84, 95% CI: 0.72–0.97) and overall (HR: 0.86, 95% CI: 0.81–0.92) mortality. However, what constitutes a good BCQS was not defined. Similarly, our high-quality surgery matrix was an independent predictor of lower index admission mortality.

We acknowledged limitations to our study. The data submitted to the BAUS cystectomy audit are normally self-submitted by the surgeon or administrative staff at the institution, which may lead to a reporting bias. While it is mandated by the BAUS, up to 20% of cases may not have been recorded, and this may mean that the reported outcomes might not reflect lower-volume surgeons that may have potentially worse outcomes. We acknowledge that the dataset does not capture accurately the use of enhanced recovery after surgery, 30- and 90-d mortality, and complication rate, as well as time from transurethral resection of bladder tumour to RC. Hence, we could not correlate high-quality surgery matrix with survival outcomes and utilised a surrogate of index admission mortality as an end point. Utilisation of preoperative chemotherapy was not incorporated into the matrix due to a high proportion of missing data. Additionally, more granular hospital characteristics such as geographical location and academic institution status were not released to ensure that surgeon- and hospital-level data remain anonymous. Our results suggest that a minimally invasive approach was associated with high-quality surgery, which is in contrast with the results of the RAZOR study [37]. This may be related to the fact that such institutions would have adopted
Table 3 – Multilevel hierarchical mixed-effect logistic regression model to determine variables independently associated with inpatient mortality in bladder cancer patients treated with radical cystectomy

| Variables                                  | Odds ratio | 95% CI  | p value |
|--------------------------------------------|------------|---------|---------|
| High-quality surgery                       | 0.38       | 0.16–0.87 | 0.021  |
| Patient-specific variables                 |            |         |         |
| Age (continuous)                           | 1.02       | 1.00–1.04 | 0.024  |
| Charlson Comorbidity Index                 |            |         |         |
| 0                                          | Reference  | Reference |         |
| 1                                          | 1.05       | 0.53–2.09 | 0.894  |
| 2                                          | 1.09       | 0.55–2.16 | 0.807  |
| ≥3                                         | 1.92       | 1.00–3.70 | 0.051  |
| Unknown                                    | 0.74       | 0.30–1.81 | 0.503  |
| Anaerobic threshold                        |            |         |         |
| <11                                        | Reference  | Reference |         |
| ≥11                                        | 1.12       | 0.46–2.70 | 0.805  |
| Unknown                                    | 0.74       | 0.34–1.62 | 0.452  |
| Body mass index                            |            |         |         |
| <24.7                                      | Reference  | Reference |         |
| 24.8–27.4                                  | 0.62       | 0.30–1.27 | 0.191  |
| 27.5–30.5                                  | 0.57       | 0.27–1.21 | 0.145  |
| ≥30.6                                      | 0.61       | 0.29–1.28 | 0.192  |
| Unknown                                    | 0.97       | 0.50–1.88 | 0.938  |
| Neoadjuvant chemotherapy use                |            |         |         |
| No                                         | Reference  | Reference |         |
| Yes                                        | 0.74       | 0.31–1.78 | 0.496  |
| Unknown                                    | 1.14       | 0.65–2.01 | 0.642  |
| Preoperative radiotherapy                   |            |         |         |
| No                                         | Reference  | Reference |         |
| Yes                                        | 0.82       | 0.33–2.03 | 0.662  |
| Unknown                                    | 1.34       | 0.61–2.92 | 0.464  |
| Year of surgery (continuous)               | 1.13       | 0.85–1.51 | 0.393  |
| Blood loss (ml)                            |            |         |         |
| <299                                       | Reference  | Reference |         |
| 300–499                                     | 1.03       | 0.56–1.87 | 0.930  |
| 500–999                                     | 0.55       | 0.26–1.14 | 0.107  |
| ≥1000                                      | 0.55       | 0.22–1.33 | 0.183  |
| Red blood cell transfusion                  |            |         |         |
| No                                         | Reference  | Reference |         |
| 1–2 units                                   | 1.72       | 0.87–3.39 | 0.118  |
| ≥3 units                                   | 3.54       | 1.54–8.17 | 0.003  |
| Unknown                                    | 2.95       | 0.77–11.24 | 0.313  |
| Cancer-specific variables                  |            |         |         |
| Tumour grade                               |            |         |         |
| Low                                        | Reference  | Reference |         |
| High                                       | 1.71       | 0.52–5.61 | 0.374  |
| Unknown                                    | 2.22       | 0.61–8.06 | 0.227  |
| Pathological T stage                       |            |         |         |
| <pT1                                       | Reference  | Reference |         |
| pT2                                        | 1.78       | 0.87–3.68 | 0.117  |
| pT3–4                                      | 2.17       | 1.20–3.94 | 0.011  |
| Unknown                                    | 2.19       | 0.65–7.37 | 0.205  |
| Pathological N stage                       |            |         |         |
| pN0                                        | Reference  | Reference |         |
| pN1+                                       | 1.03       | 0.59–1.82 | 0.911  |
| Unknown                                    | 1.49       | 0.67–3.31 | 0.323  |
| Hospital-level variables                   |            |         |         |
| Surgical approach                          |            |         |         |
| Open                                       | Reference  | Reference |         |
| Laparoscopic/robotic                       | 1.13       | 0.62–2.08 | 0.691  |
| Annual surgeon operating volume            |            |         |         |
| ≤14                                        | Reference  | Reference |         |
| 14.1–23.0                                  | 0.82       | 0.44–1.53 | 0.534  |
| 23.1–33.0                                  | 0.96       | 0.47–1.96 | 0.913  |
| ≥33.1                                      | 0.75       | 0.31–1.82 | 0.524  |
| Annual hospital operating volume           |            |         |         |
| ≤29.0                                      | Reference  | Reference |         |
| 29.1–47.0                                  | 0.97       | 0.49–1.95 | 0.937  |
| 47.1–63.0                                  | 1.09       | 0.53–2.27 | 0.809  |
| ≥63.1                                      | 0.82       | 0.32–2.10 | 0.679  |

CI = confidence interval.
a robotic platform, and the variables that we included in our multivariate regression model may not have accounted for other unknown confounding factors. It is worth nothing that the RAZOR study represents a noninferiority study with an oncological outcome primary end point and is not without limitations [38]. PSM was defined as soft tissue PSM and/or CIS, and we acknowledge that this may not entirely reflect quality surgery as ureteral frozen section is not the standard practice and oncological relevance of CIS PSM is debatable. Finally, patient-reported quality of life outcomes were not captured within this dataset.

5. Conclusions

We report that there remains a significant association between annual surgeon operating volume and minimally invasive RC, with the attainment of high-quality surgery in patients. Patients treated with high-quality surgery were predicted to have lower index admission mortality. Our results support the role of centralisation of complex oncology as well as the implementation of a high-quality assurance programme to improve the delivery of care for complex oncological surgery such as RC.

Author contributions: Wei Shen Tan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Tan, Trinh, Kelly.
Acquisition of data: Tan, Fowler.
Analysis and interpretation of data: Tan, Leow, Marchese, Sridhar, Hellawell, Mossanen, Teoh, Fowler, Colquhoun, Cresswell, Catto, Trinh, Kelly.
Drafting of the manuscript: Tan.
Critical revision of the manuscript for important intellectual content: Leow, Colquhoun, Catto, Trinh, Kelly.
Statistical analysis: Tan, Marchese.
Obtaining funding: None.
Administrative, technical, or material support: None.
Supervision: Trinh, Kelly.
Other: None.

Financial disclosures: Wei Shen Tan certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Funding/Support and role of the sponsor: None.

Acknowledgements: Data were provided by the British Association of Urological Surgeons.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi: https://doi.org/10.1016/j.euros.2021.08.005.

References

[1] Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 2021;79:82–104.
[2] Tan WS, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treat Rev 2016;47:22–31.
[3] Goossens-Laan CA, Lelieveld AM, Verhoeven RH, et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer 2014;135:905–12.
[4] Noon A, Albertsen P, Thomas F, Rosario D, Catto J. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. Br J Cancer 2013;108:1534–40.
[5] Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164–76.
[6] Tan WS, Lamb BW, Kelly JD. Complications of radical cystectomy and orthotopic reconstruction. Adv Urol 2015;2015:323157.
[7] Juber L, Pang KH, Groves R, et al. Impact of anaesthetist volume on radical cystectomy outcomes. Eur Urol Focus 2021;7:17–23.
[8] Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–61.
[9] Collins JW, Patel H, Adding C, et al. Enhanced recovery after robot-assisted radical cystectomy: EAU Robotic Urology Section Scientific Working Group consensus view. Eur Urol 2016;70:649–60.
[10] Powles T, Kelly J. Innovation: London Cancer—multidisciplinary approach to urological cancer. Nat Rev Clin Oncol 2013;10:609.
[11] Williams SB, Ray-Zack MD, Hudgins HK, et al. Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review. Eur Urol Oncol 2019;2:265–73.
[12] Mariappan P, Johnston A, Padovani L, et al. Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland’s Quality Performance Indicators Programme. Eur Urol 2020;78:520–30.
[13] Cole AP, Ramaswamy A, Harmouch S, et al. Multilevel analysis of readmissions after radical cystectomy for bladder cancer in the USA: does the hospital make a difference? Eur Urol Oncol 2019;2:349–54.
[14] Leow JJ, Catto JW, Elfathathou JA, et al. Quality indicators for bladder cancer services: a collaborative review. Eur Urol 2020;78:43–59.
[15] Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004;22:2781–9.
[16] Novara G, Stavek RS, Karakiewicz PI, et al. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 2010;183:2165–70.
[17] Gschwend JE, Heck MM, Lehmann J, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 2019;75:604–11.
[18] Dixon E, Datta I, Sutherland FR, Vauthney JN. Blood loss in surgical oncology: neglected quality indicator? J Surg Oncol 2009;99:508–12.
[19] Carson JL, Poses RM, Spence RK, Bonavita G. Severity of anemia and operative mortality and morbidity. Lancet 1988;1:727–9.
[20] Tan WS, Lamb BW, Tan MY, et al. In-depth critical analysis of complications following robot-assisted radical cystectomy with intracorporeal urinary diversion. Eur Urol Focus 2017;3:273–9.
[21] Kim SP, Shah ND, Karnes RJ, et al. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol 2012;187:2011–7.

[22] Pang KH, Groves R, Venugopal S, Noon AP, Catto JW. Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy. Eur Urol 2018;73:363–71.

[23] Tan WS, Tan MY, Lamb BW, et al. Intracorporeal robot-assisted radical cystectomy, together with an enhanced recovery programme, improves postoperative outcomes by aggregating marginal gains. BJU Int 2018;121:632–9.

[24] Williams SB, Cumberbatch MG, Kamat AM, et al. Reporting radical cystectomy outcomes following implementation of enhanced recovery after surgery protocols: a systematic review and individual patient data meta-analysis. Eur Urol 2020;78:719–30.

[25] Jefferies ER, Cresswell J, McGrath JS, et al. Open radical cystectomy in England: the current standard of care—an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data. BJU Int 2018;121:880–5.

[26] Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer 2008;112:2401–8.

[27] Wilson TG, Guru K, Rosen RC, et al. Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel. Eur Urol 2015;67:363–75.

[28] Tan WS, Khetrapal P, Tan WP, Rodney S, Chau M, Kelly JD. Robotic assisted radical cystectomy with extracorporeal urinary diversion does not show a benefit over open radical cystectomy: a systematic review and meta-analysis of randomised controlled trials. PLoS One 2016;11:e0166221.

[29] Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics 1982;38:1011–6.

[30] Rao JN, Scott AJ. On chi-squared tests for multiway contingency tables with cell proportions estimated from survey data. Ann Stat 1984;12:46–60.

[31] Natarajan S, Lipsitz SR, Fitzmaurice GM, et al. An extension of the Wilcoxon rank sum test for complex sample survey data. J R Stat Soc Ser C (Appl Stat) 2012;61:653–64.

[32] National Institute for Clinical Excellence. Guidance on cancer services: improving outcomes in urological cancers. The manual. London, UK: National Institute for Clinical Excellence; 2002.

[33] Jallad S, Hounsme J, Verne J, Mayer E. Where are we with improving outcome guidance? An update on pelvic urological services in the NHS. J Clin Urol 2017;10:29–33.

[34] Cathcart P, Sridhara A, Ramachandran N, Briggs T, Nathan S, Kelly J. Achieving quality assurance of prostate cancer surgery during reorganisation of cancer services. Eur Urol 2015;68:22–9.

[35] Hussein AA, Dibaj S, Hinata N, et al. Development and validation of a quality assurance score for robot-assisted radical cystectomy: a 10-year analysis. Urology 2016;97:124–9.

[36] Khanna A, Saarel O, Lawson K, et al. Hospital quality metrics for radical cystectomy: disease specific and correlated to mortality outcomes. J Urol 2019;202:490–7.

[37] Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018;391:2525–36.

[38] Khetrapal P, Catto JW, Kelly JD. Robot-assisted versus open cystectomy in the RAZOR trial. Lancet 2019;393:644–5.